Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Piyawan Tienchaiananda"'
Autor:
Fabio Augusto Barros Schutz, Ekaphop Sirachainan, Shanggar Kuppusamy, Nguyen Thi Thai Hoa, Thitiya Dejthevaporn, Badrulhisham Bahadzor, Vu Quang Toan, Phichai Chansriwong, Adlinda Alip, Nguyen Thi Minh Hue, Napa Parinyanitikul, Ai Lian Tan, Vu Dinh Khanh Hoang, Piyawan Tienchaiananda, Sai Naga Deepak Chinchapattanam, Amit Garg
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Aims: Clinical decision making is challenging in men with metastatic prostate cancer (mPC), as heterogeneity in treatment options and patient characteristics have resulted in multiple scenarios with little or no evidence. The South East Asia Expert P
Externí odkaz:
https://doaj.org/article/b0c04b1a3e17433096b3ca7eae3696de
Autor:
Amit Garg, Napa Parinyanitikul, Ai Lian Tan, Fabio Augusto Barros Schutz, Shanggar Kuppusamy, Vu Dinh Khanh Hoang, Badrulhisham Bahadzor, Ekaphop Sirachainan, Vu Quang Toan, Nguyen Thi Thai Hoa, Adlinda Alip, Phichai Chansriwong, Sai Naga Deepak Chinchapattanam, Nguyen Thi Minh Hue, Thitiya Dejthevaporn, Piyawan Tienchaiananda
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology
Aims: Clinical decision making is challenging in men with metastatic prostate cancer (mPC), as heterogeneity in treatment options and patient characteristics have resulted in multiple scenarios with little or no evidence. The South East Asia Expert P
Autor:
Schutz, Fabio Augusto Barros, Ekaphop Sirachainan, Shanggar Kuppusamy, Nguyen Thi Thai Hoa, Thitiya Dejthevaporn, Badrulhisham Bahadzor, Toan, Vu Quang, Phichai Chansriwong, Adlinda Alip, Nguyen Thi Minh Hue, Napa Parinyanitikul, Tan, Ai Lian, Hoang, Vu Dinh Khanh, Piyawan Tienchaiananda, Chinchapattanam, Sai Naga Deepak, Garg, Amit
Supplemental material, sj-pdf-1-tam-10.1177_1758835920985464 for Optimizing outcomes for patients with metastatic prostate cancer: insights from South East Asia Expert Panel by Fabio Augusto Barros Schutz, Ekaphop Sirachainan, Shanggar Kuppusamy, Ngu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::31f1a9153f68603a177ce54b329e21cc
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 5 (2015)
Frontiers in Oncology, Vol 5 (2015)
Type 1 insulin like growth factor receptor (IGF-1R) targeted therapies showed compelling pre-clinical evidence; however, to date, this has failed to translate into patient benefit in Phase 2/3 trials in unselected patients. This was further complicat